Cystatin C is a Valuable Marker for Predicting Future Cardiovascular Diseases in Type 2 Diabetic Patients.
10.4093/kdj.2008.32.6.488
- Author:
Seung Hwan LEE
1
;
Kang Woo LEE
;
Eun Sook KIM
;
Ye Ree PARK
;
Hun Sung KIM
;
Shin Ae PARK
;
Mi Ja KANG
;
Yu Bai AHN
;
Kun Ho YOON
;
Bong Yun CHA
;
Ho Young SON
;
Hyuk Sang KWON
Author Information
1. Department of Internal Medicine, The Catholic University of Korea, Korea.
- Publication Type:Original Article
- Keywords:
Biomarkers;
Cardiovascular disease;
Cystatin C;
Type 2 diabetes
- MeSH:
Biomarkers;
Cardiovascular Diseases;
Carotid Intima-Media Thickness;
Coronary Disease;
Creatinine;
Cystatin C;
Fibrinogen;
Hemoglobins;
Homocysteine;
Humans;
Lipoprotein(a);
Risk Factors;
Stroke;
Uric Acid
- From:Korean Diabetes Journal
2008;32(6):488-497
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Recent studies suggest that serum Cystatin C is both a sensitive marker for renal dysfunction and a predictive marker for cardiovascular diseases. We aimed to evaluate the association between Cystatin C and various biomarkers and to find out its utility in estimating risk for cardiovascular diseases in type 2 diabetic patients. METHODS: From June 2006 to March 2008, anthropometric measurements and biochemical studies including biomarkers for risk factors of cardiovascular diseases were done in 520 type 2 diabetic patients. A 10-year risk for coronary heart diseases and stroke was estimated using Framingham risk score and UKPDS risk engine. RESULTS: The independent variables showing statistically significant associations with Cystatin C were age (beta = 0.009, P < 0.0001), hemoglobin (beta = -0.038, P = 0.0006), serum creatinine (beta = 0.719, beta < 0.0001), uric acid (beta = 0.048, P = 0.0004), log hsCRP (beta = 0.035, P = 0.0021) and homocysteine (beta = 0.005, P = 0.0228). The levels of microalbuminuria, carotid intima-media thickness, fibrinogen and lipoprotein (a) also correlated with Cystatin C, although the significance was lost after multivariate adjustment. Calculated risk for coronary heart diseases increased in proportion to Cystatin C quartiles: 3.3 +/- 0.4, 6.2 +/- 0.6, 7.6 +/- 0.7, 8.4 +/- 0.7% from Framingham risk score (P < 0.0001); 13.1 +/- 0.9, 21.2 +/- 1.6, 26.1 +/- 1.7, 35.4 +/- 2.0% from UKPDS risk engine (P < 0.0001) (means +/- SE). CONCLUSIONS: Cystatin C is significantly correlated with various emerging biomarkers for cardiovascular diseases. It was also in accordance with the calculated risk for cardiovascular diseases. These findings verify Cystatin C as a valuable and useful marker for predicting future cardiovascular diseases in type 2 diabetic patients.
